MEOBF MESOBLAST LTD
Price Chart
Executive Summary
Mesoblast received FDA clearance to proceed directly to a registrational trial for Ryoncil in Duchenne muscular dystrophy (DMD), a significant step forward for a devastating disease. This is a material positive development.
Actionable Insight
This is a major regulatory milestone that de-risks the DMD program. The direct path to a registrational trial is a strong signal of FDA confidence. The partnership with PPMD should accelerate patient recruitment. Monitor for trial initiation and enrollment updates.
Key Facts
- FDA has granted Investigational New Drug (IND) clearance to directly proceed to a registrational clinical trial for Ryoncil in Duchenne muscular dystrophy (DMD).
- The trial will randomize 76 patients aged 5 to 9 years to either Ryoncil or placebo.
- The trial's primary endpoint will be time-to-stand at nine months, a validated FDA endpoint for approval.
- Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to support patient identification and trial awareness.
Financial Impact
Significant potential for a new revenue stream if approved. DMD affects ~15,000 children in the U.S.
Risk Factors
- Clinical trial may not meet its primary endpoint.
- Safety issues could arise in the trial.
- Competitors may develop alternative DMD therapies.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000043 |
| Exhibit: exhibit991dmd.htm | 0001345099-26-000043 |
| Document: 0001345099-26-000043-index-headers.html | 0001345099-26-000043 |
| Document: 0001345099-26-000043-index.html | 0001345099-26-000043 |
| Document: 0001345099-26-000043.txt | 0001345099-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
23d ago
|
6-K
| — | awaiting T+20 | — | — |
|
Apr 17, 2026
5w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.70 (+6.25%) |
|
Apr 15, 2026
5w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.70 (+6.25%) |
|
Apr 8, 2026
6w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.70 (+6.25%) |
|
Apr 8, 2026
6w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.70 (+6.25%) |
|
Apr 8, 2026
6w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.70 (+6.25%) |
|
Apr 8, 2026
6w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.70 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access